NCT00005858已完成1 期
Phase I Study of LMB-9, a Recombinant Disulfide Stabilized Anti-Lewis Y Immunotoxin Admistered by Continuous Infusion
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 25
- 试验地点
- 4
研究概览
简要总结
Phase I trial to study the effectiveness of LMB-9 immunotoxin in treating patients who have advanced colon, breast, non-small cell lung, bladder, pancreatic, or ovarian cancer. The LMB-9 immunotoxin can locate tumor cells and kill them without harming normal cells.
详细描述
OBJECTIVES:
I. Determine the maximum tolerated dose of LMB-9 immunotoxin in patients with advanced colon, breast, non-small cell lung, bladder, pancreas, or ovarian cancer.
II. Assess the toxicity and pharmacokinetics of this treatment regimen in these patients.
III. Determine the clinical responses in patients treated with this regimen.
OUTLINE: This is a dose-escalation study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (4)
Loading locations...
相似试验
已完成
1 期
LMB-9 Immunotoxin in Treating Patients With Advanced Solid TumorsBreast CancerBladder CancerColorectal CancerLung CancerPancreatic CancerGastric CancerEsophageal CancerNCT00019435National Cancer Institute (NCI)
Unknown
1 期
LMB-9 Immunotoxin in Treating Patients With Advanced Pancreatic, Esophageal, Stomach, Colon, or Rectal CancerColorectal CancerPancreatic CancerGastric CancerEsophageal CancerNCT00010270University Hospital Freiburg50
已完成
1 期
Study of NS-9 in Patients With Liver MetastasesLiver NeoplasmsNeoplasm MetastasisLocal Neoplasm RecurrencesNCT00094003NS Pharma, Inc.20
已完成
1 期
B-Lymphocyte Stimulator (BLyS) To Treat Selective IgA DeficiencyIgA DeficiencyNCT00024934National Cancer Institute (NCI)20
已完成
1 期
TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular LymphomaGrade 1 Follicular LymphomaGrade 2 Follicular LymphomaGrade 3a Follicular LymphomaRecurrent Follicular LymphomaRefractory Follicular LymphomaMarginal Zone LymphomaMantle Cell LymphomaNCT02927964Robert Lowsky21